Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE)

Author(s): Suparna Chatterjee*, Dwaipayan Sarathi Chakraborty, Shouvik Choudhury and Sandeep Lahiry

Volume 14, Issue 1, 2022

Published on: 20 January, 2022

Page: [20 - 23] Pages: 4

DOI: 10.2174/2589977513666211206100749

Price: $65

Abstract

The incidence of carbapenem-resistant gram-negative (CRGNB) bacterial infections has increased globally. The wide diversity of strains, multiplicity of infections, and rapid development and spread of resistance are a matter of great concern both in community and hospital settings.

Cefiderocol is a novel injectable siderophore containing cephalosporin with potent microbicidal activity against most carbapenem-resistant Enterobacteriaceae (CRE). It has recently been approved by USFDA for the treatment of complicated urinary tract infections (cUTI) caused by susceptible gram-negative microorganisms.

This review focuses on the salient pharmacological profile of the drug and the clinical studies that were undertaken.

Cefiderocol is first in class injectable siderophore cephalosporin showing potency against carbapenem- resistant Enterobacteriaceae. It has recently been approved by US FDA for the treatment of adult patients with complicated urinary tract infections (cUTI) caused by susceptible Gram-negative microorganisms, where there are limited or no alternative treatment options.

Keywords: Antibiotic, cephalosporin, complicated urinary tract infection, treatment, carbapenem-resistant Enterobacteriaceae, cefiderocol.

« Previous Next »
Graphical Abstract

[1]
World Health Organization Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_ Summary_25Feb-ET_NM_WHO.pdf (Accessed 1 February 2019).
[2]
Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18(3): 318-27.
[http://dx.doi.org/10.1016/S1473-3099(17)30753-3] [PMID: 29276051]
[3]
Jean SS, Hsueh SC, Lee WS, Hsueh PR. Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 2019; 17(5): 307-9.
[http://dx.doi.org/10.1080/14787210.2019.1612240] [PMID: 31055983]
[4]
Watkins RR, Van Duin D. Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria. F1000Res 2019; 8: 121.
[http://dx.doi.org/10.12688/f1000research.16517.2]
[5]
US Food & Drug Administration (FDA). FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance [Media release]. 2019. Available from: http://www.fda.gov(accessed 14 Nov 2019).
[6]
Wu JY, Srinivas P, Pogue JM. Cefiderocol: A novel agent for the management of multidrug-resistant Gram-negative organisms. Infect Dis Ther 2020; 9(1): 17-40.
[http://dx.doi.org/10.1007/s40121-020-00286-6] [PMID: 32072491]
[7]
Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs 2019; 79(3): 271-89.
[http://dx.doi.org/10.1007/s40265-019-1055-2] [PMID: 30712199]
[8]
Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother 2018; 63(1): e01801-18.
[http://dx.doi.org/10.1128/AAC.01801-18] [PMID: 30323050]
[9]
Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother 2017; 62(1): e01454-17.
[http://dx.doi.org/10.1128/AAC.01454-17] [PMID: 29061741]
[10]
Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 2016; 60(7): 4384-6.
[http://dx.doi.org/10.1128/AAC.03098-15] [PMID: 27139465]
[11]
Laurent D, Drew R, Wilson D. Developments for the treatment of invasive infections due to multidrug-resistant Acinetobacter baumannii. Univ Louisville J Respir Infect 2019; 3: 3.
[http://dx.doi.org/10.18297/jri/vol3/iss2/3]
[12]
Ito A, Nishikawa T, Ishii R, et al. 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies. Open Forum Infect Dis 2018; 5(Suppl. 1): S251.
[http://dx.doi.org/10.1093/ofid/ofy210.703]
[13]
Malik S, Kaminski M, Landman D, Quale J. Cefiderocol resistance in acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob Agents Chemother 2020; 64(11): e01221-20.
[http://dx.doi.org/10.1128/AAC.01221-20] [PMID: 32868330]
[14]
Fetroja (Cefiderocol). Package insert.
[15]
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62(2): e01968-17.
[http://dx.doi.org/10.1128/AAC.01968-17] [PMID: 29158270]
[16]
Tsuji M, Hackel M, Echols R, Yamano Y, Sahm D. In vitro activity of Cefiderocol against globally collected carbapenem-resistant gram-negative bacteria isolated from urinary track source: sidero-cr-2014/2016. Open Forum Infect Dis 2017; 4(Suppl. 1): S366.
[http://dx.doi.org/10.1093/ofid/ofx163.895]
[17]
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18(12): 1319-28.
[http://dx.doi.org/10.1016/S1473-3099(18)30554-1] [PMID: 30509675]
[18]
Katsube T, Yamano Y, Ariyasu M, Nagata T. Y. Matsunaga RE. Cefiderocol (S-649266) for nosocomial pneumonia caused by gram-negative pathogens: study design of APEKS-NP, a phase 3 double-blind parallel-group randomized clinical trial. Am J Respir Crit Care Med 2018; 197: A3290.
[19]
FDA. Cefiderocol meeting of the antimicrobial drugs advisory committee (AMDAC). In: October 16, 2019: Antimicrobial Drugs Advisory Committee Meeting Announcement. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-16-2019-antimicrobial-drugs-advisory-committee-meeting-announcement-10162019-10162019.
[20]
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2020; 21(2): 226-40.
[http://dx.doi.org/10.1016/S1473-3099(20)30796-9]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy